| 黄 林,杨洪伟,邓树忠,陈 明,黄 松,陈 翔,刘明华.香连片治疗脾胃湿热型慢性非萎缩性胃炎的临床疗效及作用机制研究[J].,2020,(5):988-991 |
| 香连片治疗脾胃湿热型慢性非萎缩性胃炎的临床疗效及作用机制研究 |
| Study on the Clinical Effect and Mechanism of Xianglian Tablet in Treating Chronic Non-atrophic Gastritis with Dampness and Heat of Spleen and Stomach |
| 投稿时间：2019-12-01 修订日期：2019-12-31 |
| DOI：10.13241/j.cnki.pmb.2020.05.042 |
| 中文关键词: 香连片 脾胃湿热型 慢性非萎缩性胃炎 疗效 |
| 英文关键词: Xianglian tablets Dampness-heat of spleen and stomach Chronic non-atrophic gastritis Clinical effect |
| 基金项目:四川省卫生计生委科研基金项目（16PJ0372） |
|
| 摘要点击次数: 815 |
| 全文下载次数: 584 |
| 中文摘要: |
| 摘要 目的：观察香连片治疗脾胃湿热型慢性非萎缩性胃炎（CNAG)的临床疗效，并探讨香连片治疗CNAG的作用机制。方法：选择2017年1月-2019年7月我院门诊及住院的100例脾胃湿热型CNAG患者，按随机数字表法分成对照组和观察组，每组各50例。对照组给予胃复春片口服，4片/次，3次/d；观察组予香连片口服，5片/次，3次/d，3个月为1疗程，治疗1疗程后采用酶联免疫法(ELISA)检测血清肿瘤坏死因子-α(TNF-α)、白介素lβ(IL-lβ)及白介素2（IL-2）水平，比较治疗前后患者上腹胀满、胃脘痛、反酸、口苦、恶心呕吐的症状积分，并统计两组疗效及不良反应发生情况。结果：治疗后，观察组的总有效率为94.00%(47/50)，显著高于对照组的80.00%(40/50)（P＜0.05）；两组血清IL-2水平升高，TNF-α、IL-lβ水平降低，且观察组上述指标改善情况更优（P＜0.05）；两组患者上腹胀满、胃脘痛、反酸、口苦、恶心呕吐的症状积分均降低，且观察组上述症状积分低于对照组（P＜0.05）；两组均未见明显不良反应发生。结论：香连片治疗脾胃湿热型CNAG的疗效令人满意，可较好地缓解脾胃湿热型CNAG患者上腹胀满、胃脘痛、反酸、口苦、恶心呕吐的症状，其可能是通过抑制促炎因子TNF-α、IL-lβ的产生，促进抑炎因子IL-2的分泌，提高机体的抗炎能力，从而起到治疗作用。 |
| 英文摘要: |
| ABSTRACT Objective: To observe the clinical effect of xianglian tablets in treating chronic non-atrophic gastritis (CNAG) with dampness-heat of spleen and stomach, and to explore the mechanism of xianglian tablets in treating CNAG. Methods: 100 CNAG patients with dampness and heat of spleen and stomach from the outpatient department and inpatient department of our hospital from January 2017 to July 2019 were selected, which were divided into control group and observation group according to the random number table method, 50 cases in each group. The control group was given weifuchun tablets orally, 4 tablets each time, 3 times one day. The observation group was given coumarin orally, 5 tablets each time, 3 times one day, 3 months for a course of treatment, after one course of treatment, serum levels of tumor necrosis factor-α (TNFα), interleukin-lβ (IL-lβ) and interleukin-2 (IL-2) were detected by enzyme-linked immunosorbent assay (ELISA), and the symptom scores of patients with upper abdominal distension, epigastric pain, acid reflux, bitter mouth, nausea and vomiting before and after treatment were compared. Results: After treatment, the total effective rate of the observation group was 94.00%(47/50), significantly higher than 80.00%(40/50) in the control group (P<0.05). The levels of serum IL-2 in the two groups increased, while the levels of TNF-α and IL-lβ levels decreased, and the improvement of the above indicators in the observation group was better (P<0.05). The symptom scores of upper abdominal distension, epigastric pain, acid reflux, bitter mouth, nausea and vomiting in the two groups were all reduced, and the symptom scores of the observation group were lower than that of the control group (P<0.05). No significant adverse reactions were observed in both groups. Conclusion: Xianglian tablet has a satisfactory therapeutic effect on CNAG patients with dampness and heat of spleen and stomach , and can relieve the symptoms of upper abdominal distension, epigastric pain, acid regurgitation, bitter mouth, nausea and vomiting in patients with spleen and stomach damp-heat CNAG, which may promote the secretion of anti-inflammatory factor IL-2 by inhibiting the production of pro-inflammatory factors TNF-α and IL-lβ, which can improve the anti-inflammatory ability of the body, thus playing a therapeutic role. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
